Advanced cell programming
Engineered T cell immunotherapy products show significant efficacy for hematological malignancies
However, realization of the potential of this approach across a broad range of tumor types will require multiple technology solutions to address limitations of the current generation of therapies.
Our technological approach is the development of advanced T-cell engineering components designed to directly address clinical challenges. A focus on our early-stage pipeline incorporates multiple components in a single product.